Diseases /
Pancreatic Ductal Adenocarcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: An infiltrating adenocarcinoma that arises from the epithelial cells of the pancreas. It affects males more often than females and the patients are usually over 50 years of age. Microscopically it is characterized by the presence of glandular (ductal) differentiation and desmoplastic stroma formation. Signs and symptoms include pain, loss of weight, and jaundice. It grows rapidly and is usually detected after it has metastasized to other anatomic sites. The prognosis is usually poor. [1]
Pancreatic ductal adenocarcinomas most frequently harbor alterations in KRAS, TP53, CDKN2A, CDKN2B, and RNF43 [2].
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and KRAS G12D are the most common alterations in pancreatic ductal adenocarcinoma [2].
Clinical Trials
Significant Genes in Pancreatic Ductal Adenocarcinoma
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.